Biotech and Pharmaceuticals Medicine

  • Sept 20- Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity. Just hours later on Tuesday, Allergan announced it would also pay $50 million upfront and make future milestone...

  • Sept 20- Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity. Allergan's offer on Tuesday of $28.35 upfront per Tobira share is a whopping 500 percent premium to the stock's...

  • Botox-maker Allergan is bulking up its drug pipeline with two acquisitions announced Tuesday, both of which target liver disease. Allergan PLC said it's acquiring Tobira Therapeutics Inc. and two potential liver disease treatments in a deal that could be worth almost $1.7 billion. Shares of Dublin- based Allergan slipped nearly 3 percent, or $6.62, to $238.67.

  • Sept 20- Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to $1.7 billion, to gain access to its experimental therapies for a fatty liver disease called NASH. Dublin- based Allergan said Tobira shareholder could get up to $49.84 per share contingent on the company achieving certain milestones. About 30 percent of people in the United...

  • WASHINGTON, Sept 19- The U.S. International Trade Commission said it will investigate certain sleep-disordered breathing treatment mask systems and components following a complaint by ResMed Inc and ResMed Corp that imported products violated its patents.

  • The drug was the first in the United States to be approved for the devastating disease and Sarepta's stock nearly doubled in value to $56.18 following the decision. Tim Lugo, an analyst with William Blair, estimates the drug will generate global peak annual sales of close to $2 billion. The FDA also granted Sarepta a rare pediatric disease voucher which...

  • The approval came despite an internal dispute among Food and Drug Administration officials that ultimately had to be resolved by the agency's chief. The FDA cleared Sarepta Therapeutics' Exondys 51 for a rare form of Duchenne muscular dystrophy, a deadly inherited disease that affects boys. It's the first FDA approval for the degenerative condition, which...

  • The FDA said Sarepta was required to conduct a trial to confirm the drug's effectiveness, without which the regulator may withdraw approval. Until now there have been no FDA- approved drugs for DMD, and pressure has been increasing on the regulator to swiftly approve treatments. The FDA issued a scathing review of the drug in April, suggesting its perceived...

  • For more than a decade, members of a little-known group called the Pain Care Forum have blanketed Washington with messages touting prescription painkillers' vital role in the lives of millions of Americans, creating an echo chamber that has quietly derailed efforts to curb U.S. consumption of the drugs, which accounts for two-thirds of the world's usage.

  • GSK PKG

    GlaxoSmithKline's Andrew Witty says drugs must be priced responsibly, with a balance between drug access and innovation reward.

  • Sept 16- Johnson& Johnson said it would buy Abbott Laboratories' eye care business for about $4.33 billion in cash. Abbott Medical Optics reported sales of $1.1 billion for 2015, J&J said on Friday. The Wall Street Journal earlier reported that Abbott was in talks to sell the business to J&J.

  • Sept 16- U.S. drugmaker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended. The Committee for Medicinal Products for Human Use gave a positive opinion for Ibrance to be used in combination with two existing therapies in women who have received prior endocrine...

  • Sept 16- U.S. drugmaker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended. The Committee for Medicinal Products for Human Use gave a positive opinion for Ibrance to be used in combination with two existing therapies in women who have received prior endocrine...

  • COPENHAGEN, Sept 16- Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent according to the keenly awaited results of a clinical trial released on Friday. Novo announced in April that the so-called SUSTAIN 6 trial had significantly cut the risk of major adverse cardiovascular events, but the scale of...

  • Sept 15- The U.S. Food and Drug Administration on Thursday approved a pill that combines aspirin and the acid-fighting drug omeprazole to guard against gastric ulcers in patients who require daily aspirin. The pill, Yosprala, was developed by Canada- based Aralez Pharmaceuticals Inc, whose shares rose nearly 10 percent on the news. In an interview, Aralez's chief...

  • Trump in 'excellent health' - Doctor's letter

    CNBC's John Harwood reports on the release of a new letter from Donald Trump's doctor regarding his health records.

  • The FDA confirmed on Wednesday that Dr. Farkas was seen as the leading voice within the FDA arguing against the approval of the drug and the author of a scathing critique of the company's application. Janet Woodcock, the head of the FDA's pharmaceuticals division, appeared willing from the beginning to support approval pending the outcome of a confirmatory...

  • The committee, which convened to advise the FDA on whether to approve the drug, voted unanimously that the treatment has no more effect on the disease than a placebo over a two-year period. The FDA is not obliged to follow the advice of its advisory committees but typically does so. The company subsequently initiated a new late-stage trial which it said...

  • The FDA confirmed on Wednesday that Dr. Farkas was seen as the leading voice within the FDA arguing against the approval of the drug and the author of a scathing critique of the company's application. Suntrust Robinson Humphrey said Farkas's departure at this juncture would further indicate that there is turmoil within the FDA on what to do with eteplirsen.

  • Russian hackers leak Simone Biles medical data

    The Olympic gold medalist defends her use of certain medicines for ADHD via Twitter.